When cardiomyopathies are associated with conduction disease or higher arrhythmogenic potential, the increased likelihood of changes in certain genes (e.g., SCN5A, LMNA) warrant closer surveillance and specific intervention from a cardiac electrophysiologist and a heart failure/cardiomyopathy specialist (2). This evidence concerns the gene SCN5A and cardiomyopathy.